Janssen Research & Development
See all stories related to Janssen Research & Development
A condition called fetal and neonatal alloimmune thrombocytopenia (FNAIT) can be deadly in newborns. That’s why Johnson & Johnson is passionate about developing a treatment for the disorder.
The key to slowing cognitive decline is diagnosing the disease as early as possible. And that’s exactly what Johnson & Johnson scientists are relentlessly pursuing.
From a superior way to sterilize surgical products to lifesaving medicine to treat a drug-resistant disease, check out just some of the ways Johnson & Johnson has exemplified innovation—and shared its breakthroughs with the world.
Every year, roughly 80,000 Americans receive a bladder cancer diagnosis. Many endure difficult and burdensome treatments in an attempt to fight the disease. But new innovations just might change that.
For Colitis and Crohn’s Disease Awareness Week, learn about the challenges of this painful condition—and why Johnson & Johnson continues to seek new treatment options.
Sid Jain, a leader on the pharmaceutical R&D data science team at Johnson & Johnson, knows that new and better treatment options change lives. And being a Crohn’s disease patient himself has supercharged his mission to help revolutionize the research process.
Lee-Anne James is a Janssen clinical research manager whose home base is Australia. That is, when she and her family aren’t donating their time to Mercy Ships to help treat people who lack access to lifesaving healthcare.
We spoke to a scientist behind a treatment for the disease that was recently FDA-approved for adolescents ages 12 to 18 to learn how it could give them new hope.
For Pregnancy and Infant Loss Awareness Month, learn how one woman advocated for herself and fought to complete her family after she was diagnosed with hemolytic disease of the fetus and newborn—and why Johnson & Johnson is committed to finding a better treatment for this rare and deadly blood disorder.